|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Primary Hyperparathyroidism:A Tale of Two Cities Revisited-New York and Shanghai显示文摘In the 1970s,with the advent of biochemical multichannel screening in the United States and other western countries,the clinical presentation of primary hyperparathyroidism(PHPT) changed from a symptomatic to an asymptomatic disorder.However,in Asian countries,like China,PHPT did not show this evolution,but rather continued to be a symptomatic disease with target organ involvement.In this paper,we revisit the clinical features of PHPT in New York and Shanghai,representative United States and Chinese cites,over the past decade.The questions we address are whether the disease evolved in China to a more asymptomatic one and,whether in the United States further changes are evident.The results indicate that while PHPT con-tinues to present primarily as an asymptomatic disease in the United States,a new phenotype characterized by normal serum calcium and high parathyroid hormone levels,normocalcemic PHPT,has emerged.Data from Shanghai demonstrates a trend for PHPT to present more commonly as an asymptomatic disorder in China.However,most patients with PHPT in China still manifest classical symptoms,i.e.nephrolithiasis and fractures.A comparison of the two cohorts shows that Chinese patients with PHPT are younger,with higher serum calcium and PTH levels,and lower 25-hydroxyvitamin D levels than patients in New York.Normocalcemic PHPT has not yet been recognized in Shanghai.In summary,although the phenotypes of PHPT in both cities are evolving towards less evident disease,sharp clinical and biochemical differences are still apparent in PHPT as expressed in China and the United States. | Jian-min Liu Natalie E. Cusano Barbara C. Silva Lin Zhao Xiao-yan He Bei Tao Li-hao Sun Hong-yan Zhao Wen-wei Fan Megan E. Romano Guang Ning John P. Bilezikian | 2013 | Bone Research2013，1，2： | 6 |
| 2 | New Clues that May Link Osteoporosis to the Circulating Lipid Profile显示文摘Bone Mineral Density(BMD)is a gold standard for the diagnosis of osteoporosis and is also important in the assessment of fracture risk.Other risk factors have been identified that together make up fracture risk assessment tools such as FRAX.Another potential factor,circulating lipids,has been suggested because of reports linking statins to fracture risk reduction.We analyzed the lipid profile in a cohort of women diagnosed with postmenopausal osteoporosis based on bone density determination:610 women with osteoporosis(mean lumbar spine T-score-3.16±0.81,mean yrs.since menopause 15.79±8.9)were grouped according to age at evaluation(<50 years,51-60 years,61-70 years,>70 years),the presence/absence of a history of a fragility fracture,statin and/or antiresorptive drug use.There was no correlation between BMD and Body Mass Index(BMI:P>0.05,r2<0.02).However,when BMD was correlated with both BMI and the lipid profile(Triglycerides,Cholesterol,LDLc,HDLc),significant correlations were found in 5 cohorts:51-60 years with fractures(n=61,r2=0.14,P<0.01),61-70 years(n=201,r2=0.09,P<0.01)with fractures(n=88,r2=0.14,P<0.01)or without fractures(n=113,r2=0.24,P=0.02)and over 70 years(n=247,r2=0.11,P<0.01). | Catalina Poiana Valentin Radoi Mara Carsote John P. Bilezikian | 2013 | Bone Research2013，1，3： | 5 |
| 3 | Endothelial cells contain beta adrenoceptors显示文摘 | Steinberg S F Jaffe E A Bilezikian J P | 1984 | Naunyn-Schmiedebergs Arch Pharmacol1984，325，4： | 2 |
| 4 | Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image显示文摘 | Barbara C Silva William D Leslie Heinrich Resch Olivier Lamy Olga Lesnyak Neil Binkley Eugene V McCloskey John A Kanis John P Bilezikian | 2014 | J Bone Miner Res2014，，3： | 2 |
| 5 | Clinical review: Rare causes of hypercalcemia显示文摘 | Jacobs TP Bilezikian JP | 2005 | J Clin Endoerinol Metab2005，90，： | 1 |
| 6 | Osteoporosis update from the 2010 santa fe bone symposium显示文摘 | Ewiecki EM Bilezikian JP Khosla S | 2011 | J Clin Densitom2011，14，： | 1 |
| 7 | Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis:a paired biopsy study显示文摘 | Dempster DW Cosman F Kurland ES Zhou H Nieves J Woelfert L Shane E Plavetic K Muller R Bilezikian J Lindsay R | | 0，，10： | 1 |
| 8 | American Association ofClinical Endocrinologists Medical Guidelines for Clinical Practice forthe diagnosis and treatment of postmenopausal osteoporosis 显示文摘 | Watts NB Bilezikian JP Camacho PM | 2010 | Endocr Pract2010，16，3： | 1 |
| 9 | A randomized,parallel group,double-blind,multicentre study comparing the efficacy and safety of Avandamet(rosiglitazone/metformin)and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients显示文摘 | Borges JL Bilezikian JP Jones-Leone AR | 2011 | Diabetes Obes Metab2011，13，11： | 1 |
| 10 | Parathyroid hormone and the cardiovascular system 显示文摘 | Fitzpatriek LA Bilezikian JP Silverberg SJ | 2008 | Curr Osteoporos Rep2008，6，2： | 1 |
| 11 | Asymptomatic primary hyperparathyroidism 显示文摘 | Bilezikian JP Rubin M Silverberg SJ | 2006 | Arq Bras Endocrinol Metabol2006，50，4： | 1 |
| 12 | Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research 显示文摘 | Bilezikian JP Khan A Potts JT Jr | 2011 | J Bone Miner Res2011，26，10： | 1 |
| 13 | Mechanisms of anabolic therapies for osteoporosis显示文摘 | CANALIS E GIUSTINA A BILEZIKIAN JP | 2007 | N Engl J Med2007，357，9： | 1 |
| 14 | The anabolic effects of parathyroid hormone显示文摘 | Rubin MR Cosman F Lindsay R Bilezikian JP | | 0，，： | 1 |
| 15 | Mechanisms of anabolic therapies for osteoporosis显示文摘 | Canalis E Giustina A Bilezikian J P | 2007 | N Engl J Med2007，357，9： | 1 |
| 16 | The potential of parathyroid hormone as a therapy for osteoporosis 显示文摘 | Rubin MR Bilezikian JP | 2002 | Int J Fertil Womens Med2002，47，3： | 1 |
| 17 | Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop显示文摘 | Bilezikian JP Khan AA Potts JT Jr | 2009 | J Clin EndocrinoI Metab2009，94，2： | 1 |
| 18 | Summary statement from a workshop on asympto matic primary hyperparathyroidism:a perspective for the 21st century显示文摘 | Potts JT Jr Fuleihan Gel-H | 2002 | J Bone Miner Res2002，172，： | 1 |
| 19 | Glucocorti- coid-indueed osleoporosis: an update 显示文摘 | MAZZIOTTI G AN(JELl A BILEZIKIAN JP | 2006 | Trends Endoerinol Metab2006，7，4： | 1 |
| 20 | Parathyroid carcinoma:s review of 62 patients显示文摘 | Shane E Bilezikian JP | 1982 | Endocr Rev1982，3，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员